Developing innovative medicines to extend healthy lifespan
Pioneering
Prevention for
A longer healthspan
Reduced chronic
disease burden
A healthier future
Juvenescence is a clinical-stage, AI-enabled drug development company dedicated to extending healthy lifespan through innovative medicines.
Our approach centres around developing medicines that target core aging mechanisms to not only treat but eventually prevent age-related diseases.
By focusing on these core mechanisms, we are developing medicines with multi-disease potential that can have huge impact on the trajectory of early disease and even in preventative mode for healthy individuals.
Multiple Clinical Medicines from 2024
On track to have five medicines in Phase I or II trials by Q1 2025. These therapies target core aging mechanisms, offering early disease intervention to alleviate various age-related conditions.
Innovating across modalities
Our expert team develops treatments utilising a wide range of technologies, including small molecules, biologics, & cell therapies.
Longevity at the core
Our primary goal is prevention, with the notable advantage of potentially increasing lifespan by addressing fundamental aging processes.
OUR TEAM
World-class R&D Leadership
Powered by an unrivaled drug development team, we leverage cutting-edge data science approaches to unlock successful drugs in the aging and longevity space. Our team brings together over 150 years of combined pharmaceutical R&D experience and boasts multiple drug approvals.
Our leadership has an unrivalled track record for delivering value.
IN THE NEWS